AKT1 and neoplasm: Activation of NRF2 promotes tumor cells resistant to redox stress, whereas inactivation of NRF2 with the flavonoid chrysin effectively sensitizes BEL-7402/ADM tumor cells to doxorubicin by downregulating the PI3K/Akt and ERK pathways [77].